QuidelOrtho Corp Dossier
Qualitative Analysis
Business overview
QuidelOrtho Corporation (Nasdaq: QDEL) is a leading global provider of innovative in vitro diagnostics (IVD) solutions, formed through the landmark $6 billion merger of Quidel Corporation and Ortho Clinical Diagnostics in 2022. The company operates across the entire healthcare continuum, delivering fast, accurate, and reliable diagnostic results from home testing environments to hospital laboratories, clinics, and transfusion medicine centers. Its comprehensive product portfolio spans clinical chemistry, high-throughput immunoassay testing, immunohematology, and molecular diagnostics. Key proprietary platforms driving its recurring revenue model include the Vitros laboratory systems, Sofia and QuickVue point-of-care (POC) systems, and the next-generation Savanna sample-to-answer molecular diagnostics platform.
Research as of 20 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Discontinuing the development of the Savanna platform to reallocate resources toward the newly acquired LEX Diagnostics ultra-fast thermal cycling technology.
Expected impact: Accelerates growth in the point-of-care molecular diagnostics market with a platform capable of delivering multiplex RT-PCR results in 6 to 10 minutes.
Implementing comprehensive cost-saving measures including procurement optimization, facility consolidation (such as the closure of the Raritan facility), targeted staffing reductions, and exiting lower-margin businesses.
Expected impact: Aims to expand adjusted EBITDA margins to 23% in 2026 and to the mid-to-high 20% range by 2027, while significantly improving free cash flow.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Recent Acquisitions
To acquire full ownership of LEX Diagnostics and its breakthrough LEX VELO System, an ultra-fast molecular diagnostics platform designed for decentralized respiratory testing.
Financial impact: Minimal revenue contribution expected in full-year 2026, with measurable assay pull-through and associated revenue expected to scale starting in early 2027.
Strategic Partnerships
Expands QuidelOrtho's global immunoassay portfolio outside the United States by providing access to multiple high-throughput and low-to-mid volume analyzer platforms, adding over 25 new assays.
Terms: Not disclosed
Joint forces to advance education, connection, and early testing for alloimmunized pregnancies, addressing hemolytic disease of the fetus and newborn (HDFN).
Terms: Not disclosed